Brain Tunnelgenix Technologies (BTT) has obtained the US Food and Drug Administration (FDA) clearance to market its Abreu BTT 700 System for continuous temperature monitoring.

The Abreu BTT 700 System sensor is approved for placement on the skin and to be used during surgical procedures, recovery room, intensive care and general patient monitoring.

The Abreu BTT 700 System is the continuous and noninvasive device that measures temperature on the skin surface of the body with the highest thermoconductivity, the fat-free skin which overlies the Brain Temperature Tunnel (BTT).

The Abreu BTT 700 System allows automation of patient monitoring with both wired and wireless signal transmission.

BTT CEO Rick Foreman said that the FDA approval of Abreu BTT 700 System marks a successful milestone for BTT and they are excited that medical professionals and researchers will now have access to the first product in history that enables temperature to be continuously monitored on the only truly thermoconductive skin in the body.

“This breakthrough will enable clinicians to escape their dependence on invasive thermometry and surface measurements across thermal barriers. With the exception of putting a sensor directly inside the brain, studies have shown that the BTT is the only sensor capable of detecting brain hypothermia and harmful cerebral hyperthermia,” Foreman said.